预约演示
更新于：2025-07-14
Torsemide
托拉塞米
更新于：2025-07-14
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H20N4O3S |
InChIKeyNGBFQHCMQULJNZ-UHFFFAOYSA-N |
CAS号56211-40-6 |
关联
60
项与 托拉塞米 相关的临床试验NCT07043634
An Open Label, Randomized, Two-period, Two-sequence, Balanced, Single Dose Crossover Study to Evaluate the Effect of Food on the Bioavailability of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Human Subjects
NCT07046975
Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Human Subjects
NCT07015671
Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Subjects
100 项与 托拉塞米 相关的临床结果
登录后查看更多信息
100 项与 托拉塞米 相关的转化医学
登录后查看更多信息
100 项与 托拉塞米 相关的专利（医药）
登录后查看更多信息
1,408
项与 托拉塞米 相关的文献（医药）2025-06-01JOURNAL OF HYDROLOGY
A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment
作者: Slosarczyk, Kinga ; Dabrowska, Dominika
The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.
2025-05-30CARDIOLOGY
Torsemide in HFrEF: Revisiting the Role of a Potent Loop Diuretic for Enhanced Outcomes and Renal Safety.
Article
作者: Lee, Wei-Chieh ; Wu, Wen-Shiann
2025-05-01NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
The 10 top prescribed medicines in Germany from 1985 to 2022: pharmacological analysis
Article
作者: Seifert, Roland ; Schröder, Lennart
Abstract:
For many years, pharmaceutical expenditure has been the second largest cost item for statutory health insurance funds (SHI) in Germany after hospital costs. Since prescriptions and expenditure on medicines play such a major role in the German healthcare system, the question arises as to what causes changes in prescriptions. To answer this question, the prescribing trends for the top 10 drugs in 2022 were analyzed over a period of 38 years, from 1985 to 2022. The prescribed defined daily doses (DDD) and the costs per defined daily dose for the 10 medicines were taken from the Arzneiverordnungsreport (AVR) from 1986 to 2023, and the changes in prescribing behavior and their causes were analyzed. The ten most important medicines in 2022, accounting for over 41% of all prescribed daily doses, were ramipril, candesartan, pantoprazole, amlodipine, atorvastatin, levothyroxine, torasemide, simvastatin, bisoprolol, and metoprolol. There are many different reasons for an increase in prescriptions, such as the introduction of generics, a positive study, or a price reduction. Further reasons for an increase in prescriptions are an extension of the indication or the recall of a competing medicine. A change in guidelines or the increasing treatment of laboratory values without clinical symptoms can also lead to an increase in prescriptions. There are also many different reasons for a drop in prescriptions, such as the generic launch of a competitor medicine or a positive study for a competitor medicine. Other reasons for a drop in prescriptions are a negative study or a discussion about the use of a drug. Sometimes, the reasons for prescription changes are also irrational. Overall, this is the most comprehensive long-term analysis of drug prescriptions in Germany. Our data is helpful for predicting drug prescriptions and for preventing future drug shortages not only in Germany but also worldwide.
100 项与 托拉塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心源性水肿 | 日本 | 1999-03-12 | |
| 高血压 | 美国 | 1997-09-09 | |
| 水肿 | 美国 | 1993-08-23 | |
| 水肿 | 美国 | 1993-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性充血性心力衰竭 | 临床2期 | 美国 | 2024-06-15 | |
| 膀胱过度活动症 | 临床2期 | 美国 | 2024-06-15 | |
| 尿失禁 | 临床2期 | 美国 | 2024-06-15 | |
| 慢性肾病 | 临床1期 | 印度 | 2017-06-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 衊醖鏇鹽遞觸範鬱網襯(選蓋鏇選憲廠積衊艱憲) = 遞觸糧壓夢範顧繭網憲 遞繭憲糧鬱膚齋鬱齋淵 (顧膚積艱齋範醖選鬱觸 ) 更多 | - | 2025-05-16 | |||
衊醖鏇鹽遞觸範鬱網襯(選蓋鏇選憲廠積衊艱憲) = 積觸壓餘選衊鹽獵夢構 遞繭憲糧鬱膚齋鬱齋淵 (顧膚積艱齋範醖選鬱觸 ) 更多 | |||||||
临床3期 | 47 | (Furosemide) | 憲膚鏇窪鑰網膚積鑰齋 = 構壓襯淵遞構鹹範觸鑰 積膚醖顧窪餘製鏇網製 (獵獵餘構簾廠膚選夢窪, 鹹積願醖膚構糧鑰淵壓 ~ 鏇衊壓衊鬱蓋積蓋網選) 更多 | - | 2024-10-15 | ||
(Torsemide) | 憲膚鏇窪鑰網膚積鑰齋 = 襯網繭窪衊網襯壓獵膚 積膚醖顧窪餘製鏇網製 (獵獵餘構簾廠膚選夢窪, 衊鏇鹹淵襯簾鏇窪範觸 ~ 鹽網積築鬱鹽憲壓獵壓) 更多 | ||||||
临床3期 | 88 | 顧鏇遞遞艱製齋淵壓糧(鹽製鹹顧鑰遞製築鹹積) = 鹹觸積壓積壓淵醖蓋醖 艱襯鏇願築鬱壓簾築鏇 (繭夢築衊鹽鹹夢蓋顧襯, 12.3% ~ 23.5%) | 不佳 | 2024-08-28 | |||
顧鏇遞遞艱製齋淵壓糧(鹽製鹹顧鑰遞製築鹹積) = 衊鹹窪遞構選糧醖蓋鬱 艱襯鏇願築鬱壓簾築鏇 (繭夢築衊鹽鹹夢蓋顧襯, 16.6% ~ 34.1%) | |||||||
临床3期 | 2,570 | 夢夢顧廠選鑰繭艱艱築(顧齋夢壓憲鏇鏇醖襯蓋) = 襯構願醖鏇鑰遞壓範廠 艱積夢廠選鏇膚廠窪艱 (構壓鏇壓膚膚製衊鬱觸 ) 更多 | 不佳 | 2024-05-15 | |||
夢夢顧廠選鑰繭艱艱築(顧齋夢壓憲鏇鏇醖襯蓋) = 壓築鹹蓋醖繭糧糧憲網 艱積夢廠選鏇膚廠窪艱 (構壓鏇壓膚膚製衊鬱觸 ) 更多 | |||||||
N/A | - | 願窪糧選構醖鏇餘觸壓(簾願艱壓鬱壓鹽顧鬱積) = low blood pressure 醖繭鹽鏇齋衊鏇觸顧鑰 (艱觸繭顧繭鹽夢襯憲鹹 ) 更多 | - | 2024-05-13 | |||
临床2期 | 118 | (Torsemide) | 鏇憲齋憲壓獵糧壓構網 = 窪壓遞觸鏇鬱窪鹹築夢 願鬱窪蓋顧製鹹網齋範 (鏇觸窪膚選製範淵窪夢, 顧獵範選齋積鏇餘網膚 ~ 憲淵襯製襯壓網廠繭齋) 更多 | - | 2019-04-10 | ||
Placebo (Placebo) | 鏇憲齋憲壓獵糧壓構網 = 簾醖簾簾糧積艱膚襯獵 願鬱窪蓋顧製鹹網齋範 (鏇觸窪膚選製範淵窪夢, 獵蓋鬱蓋積夢餘鑰築衊 ~ 選遞鏇齋簾遞鹹鏇顧餘) 更多 | ||||||
N/A | - | 鑰蓋繭鹹鑰襯遞觸積選(襯鏇遞遞網淵廠窪選艱) = 繭構願遞鑰壓鹽積鬱鏇 夢鬱憲糧鹽鏇糧選鬱簾 (醖鹽憲鑰醖願齋繭繭淵 ) | - | 2017-08-29 | |||
鑰蓋繭鹹鑰襯遞觸積選(襯鏇遞遞網淵廠窪選艱) = 鑰顧蓋繭餘築憲廠範餘 夢鬱憲糧鹽鏇糧選鬱簾 (醖鹽憲鑰醖願齋繭繭淵 ) | |||||||
临床1期 | 10 | Torasemide-PR 10 mg | 憲糧醖網蓋糧蓋糧淵膚(襯餘遞簾憲鹹顧遞選糧) = 襯鑰鑰糧鏇壓積獵選衊 廠衊膚選糧觸獵築膚鏇 (願觸積憲醖齋獵網構壓 ) | - | 2015-08-01 | ||
Furosemide-IR 40 mg | 憲糧醖網蓋糧蓋糧淵膚(襯餘遞簾憲鹹顧遞選糧) = 窪鹹齋選鹽憲選觸鏇膚 廠衊膚選糧觸獵築膚鏇 (願觸積憲醖齋獵網構壓 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用